Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of programmed cell death, cell death resulting from activation of endogenous cellular processes. [GOC:jl]
Programmed cell death, also known as apoptosis, is a tightly regulated process essential for maintaining tissue homeostasis, development, and immunity. It involves a series of biochemical events that lead to the dismantling of the cell without causing damage to neighboring cells.
The process is initiated by various stimuli, including intrinsic (internal) and extrinsic (external) signals.
Intrinsic pathways are triggered by cellular stress, such as DNA damage, hypoxia, or nutrient deprivation. These signals activate the mitochondrial pathway, where proteins like Bax and Bak form pores in the mitochondrial membrane, releasing cytochrome c into the cytosol. Cytochrome c then binds to Apaf-1, forming the apoptosome complex. This complex activates caspase-9, a key executioner caspase, which initiates a cascade of caspase activation.
Extrinsic pathways are triggered by death receptors, such as TNF receptor 1 (TNFR1) and Fas. These receptors bind to their ligands, such as TNF-α and Fas ligand, respectively, triggering the recruitment of adaptor proteins like TRADD and FADD. This complex activates caspase-8, another executioner caspase, which can directly activate downstream caspases or indirectly through the mitochondrial pathway.
The activation of executioner caspases, including caspase-3, -6, and -7, leads to the dismantling of the cell. These caspases cleave various cellular proteins, including lamins (which break down the nuclear envelope), cytoskeletal proteins (which dismantle the cell structure), and DNA repair enzymes (which contribute to DNA fragmentation).
The dying cell exhibits characteristic morphological changes, including cell shrinkage, nuclear fragmentation, and formation of apoptotic bodies. These apoptotic bodies are engulfed by neighboring cells or macrophages, preventing inflammation and maintaining tissue integrity.
Regulation of programmed cell death is critical for maintaining cellular homeostasis and preventing uncontrolled cell proliferation, which can lead to cancer. Dysregulation of apoptosis can also contribute to various diseases, including neurodegenerative disorders, autoimmune diseases, and inflammatory diseases.
The intricate interplay of signaling pathways and effector proteins ensures that programmed cell death occurs in a controlled and specific manner, contributing to the overall health and well-being of the organism.'
"
Protein | Definition | Taxonomy |
---|---|---|
C-X-C chemokine receptor type 4 | A C-X-C chemokine receptor type 4 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P61073] | Homo sapiens (human) |
Caspase-6 | A caspase-6 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P55212] | Homo sapiens (human) |
Alpha-crystallin B chain | An alpha-crystallin B chain that is encoded in the genome of human. [PRO:DNx, UniProtKB:P02511] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
isoquinoline-1,3,4-trione | isoquinoline-1,3,4-trione: structure in first source | ||
n-methylisatin | N-methylisatin: structure given in first source | ||
zalcitabine | zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase. Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. | pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor |
plerixafor | plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2 | azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound | anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant |
25-hydroxycholesterol | 25-hydroxy steroid; oxysterol | human metabolite | |
benzylaniline | benzylaniline: major metabolite of antazoline; RN given refers to parent cpd | ||
terephthalamide | benzenedicarboxamide | ||
lanosterol | 14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid | bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | |
krh 1636 | KRH 1636: structure in first source | ||
amd 8664 | |||
acetyl-aspartyl-glutamyl-valyl-aspartal | Ac-Asp-Glu-Val-Asp-H : A tetrapeptide consisting of two L-aspartic acid residues, an L-glutamyl residue and an L-valine residue with an acetyl group at the N-terminal and with the C-terminal carboxy group reduced to an aldehyde. It is an inhibitor of caspase-3/7. acetyl-aspartyl-glutamyl-valyl-aspartal: a capase inhibitor | tetrapeptide | protease inhibitor |
5-Nitroisatin | indoles | anticoronaviral agent | |
cyclo(d-tyrosyl-arginyl-arginyl-3-(2-naphthyl)alanyl-glycyl) | oligopeptide | ||
n-acetyltyrosyl-valyl-alanyl-aspartyl aldehyde | |||
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone | |||
amd 070 | mavorixafor: a derivative of AMD3100; a CXCR4 blocker | aminoquinoline | |
wz 811 | |||
tn14003 | TN14003: synthetic antagonist 14-mer peptide inhibiting metastasis in an animal model | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
MK-8353 | MK-8353 : A member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors. MK-8353: ERK inhibitor used in oncology | aromatic ether; dihydropyridine; indazoles; methyl sulfide; N-alkylpyrrolidine; pyridines; pyrrolidinecarboxamide; secondary carboxamide; tertiary carboxamide; triazoles | antineoplastic agent; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |